Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Tacabrutideg · BGB-16673

Small molecule (PROTAC degrader) · Degrader of Bruton's tyrosine kinase (BTK) · developed by BeOne Medicines

Phase 3 Most advanced trial
ONC Developer
1 Registered trials

What is Tacabrutideg?

Tacabrutideg is an orally bioavailable PROTAC degrader that links a BTK-binding moiety to a cereblon E3 ligase-binding moiety, driving ubiquitination and proteasomal degradation of Bruton's tyrosine kinase. It is being studied in chronic lymphocytic leukemia and small lymphocytic lymphoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
BGB-16673
Drug type
Small molecule (PROTAC degrader)
Targets
Bruton's tyrosine kinase (BTK), cereblon (CRBN) (binding partner it blocks)
Mechanism
Degrader of Bruton's tyrosine kinase (BTK)
Pathways
B-cell antigen receptor signaling, BTK-mediated downstream survival signaling, CRL4-CRBN ubiquitin-proteasome degradation
Therapy area
Oncology
Developer
BeOne Medicines (ONC)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3
UNII
PF6GPZ4DYT

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06973187 Phase 3 Chronic Lymphocytic Leukemia Recruiting ONC

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma

Other drugs acting on BTK

More from BeOne Medicines

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the ONC page.

Follow ONC, the company behind Tacabrutideg

See ONC's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ONC catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.